

AWARD NUMBER:

TITLE:

PRINCIPAL INVESTIGATOR:

CONTRACTING ORGANIZATION:

REPORT DATE:

TYPE OF REPORT:

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited


The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       |                                                  |                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------|-------------------------------------------------------|--------------------------------------------------|---------------------------------------------------------|
| <b>REPORT DOCUMENTATION PAGE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                        |                                         |                                                       | <i>Form Approved</i><br><i>OMB No. 0704-0188</i> |                                                         |
| <small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b></small> |                                        |                                         |                                                       |                                                  |                                                         |
| <b>1. REPORT DATE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                        | <b>2. REPORT TYPE</b>                   |                                                       | <b>3. DATES COVERED</b>                          |                                                         |
| <b>4. TITLE AND SUBTITLE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |                                         |                                                       | <b>5a. CONTRACT NUMBER</b>                       |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       | <b>5b. GRANT NUMBER</b>                          |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       | <b>5c. PROGRAM ELEMENT NUMBER</b>                |                                                         |
| <b>6. AUTHOR(S)</b><br><br>E-Mail:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                        |                                         |                                                       | <b>5d. PROJECT NUMBER</b>                        |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       | <b>5e. TASK NUMBER</b>                           |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       | <b>5f. WORK UNIT NUMBER</b>                      |                                                         |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                        |                                         |                                                       | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  |                                                         |
| U.S. Army Medical Research and Development Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |                                         |                                                       | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>          |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                        |                                         |                                                       | <b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>    |                                                         |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |                                         |                                                       |                                                  |                                                         |
| <b>13. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                        |                                         |                                                       |                                                  |                                                         |
| <b>14. ABSTRACT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                        |                                         |                                                       |                                                  |                                                         |
| <b>15. SUBJECT TERMS</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                        |                                         |                                                       |                                                  |                                                         |
| <b>16. SECURITY CLASSIFICATION OF:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                        |                                         | <b>17. LIMITATION OF ABSTRACT</b><br><br>Unclassified | <b>18. NUMBER OF PAGES</b>                       | <b>19a. NAME OF RESPONSIBLE PERSON</b><br>USAMRDC       |
| <b>a. REPORT</b><br><br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <b>b. ABSTRACT</b><br><br>Unclassified | <b>c. THIS PAGE</b><br><br>Unclassified |                                                       |                                                  | <b>19b. TELEPHONE NUMBER</b> <i>(include area code)</i> |

## TABLE OF CONTENTS

|                                                     | <u>Page No.</u> |
|-----------------------------------------------------|-----------------|
| 1. Introduction                                     | 4               |
| 2. Keywords                                         | 4               |
| 3. Accomplishments                                  | 4               |
| 4. Impact                                           | 11              |
| 5. Changes/Problems                                 | 11              |
| 6. Products                                         | 11              |
| 7. Participants & Other Collaborating Organizations | 11              |
| 8. Special Reporting Requirements                   | 12              |
| 9. Appendices                                       | N/A             |
| 10. References                                      | N/A             |

**1. INTRODUCTION:** Human Genome Wide Association Studies found a significant risk of Type 2 Diabetes Mellitus (T2DM) in single nucleotide polymorphisms in the *cdkal1* gene. The *cdkal1* gene is remote from the insulin gene and with the surprising function of a specific tRNA modification. Population studies and case control studies acquired evidence of the connection between Cdkal1 protein and insulin production over the years (Figure 1). To obtain biochemical proofs directly linking potential SNPs to their roles in insulin production and availability is challenging, but the development of Cdkal1 knock out mice and knock out cell lines made it possible to extend our knowledge towards therapeutic field of diabetic research. We produced and characterized a knock down of the *cdkal1* gene using small interfering and short hairpin RNA in the NIT-1 cell line, a  $\beta$ -cell line inducible for insulin (**Major Task 1**). The knock down resulted in reduced levels of *cdkal1* and mature insulin mRNAs, increased the level of precursor insulin mRNA, decreased Cdkal1 and insulin proteins, and diminished modification of tRNA<sup>Lys3</sup> from t<sup>6</sup>A<sub>37</sub> to ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> (**Major Task 2**), the specified function of Cdkal1 (**Major Task 3**, manuscript publication). We further determined that tRNA<sup>Lys3</sup> lacking ms<sup>2</sup>- is incapable of establishing hydrophobic stabilization to decode the wobble codon AAG.



**Figure 1. A. Human Insulin Processing.** Insulin mRNA is translated into one peptide that will undergo cleavage and linkages via disulfide bridges. One of two important cleavage sites is K88-R89. A preproinsulin mRNA necessitates tRNA<sup>Lys3</sup> (B.) with its fully modified anticodon loop nucleosides to accurately read the Lys AAG codon. The resulting peptide is composed of a signal sequence, A-chain, B-chain and C-peptide, the A- and B-chain associate into mature insulin. **B. Human tRNA<sup>Lys3</sup>.** tRNA<sup>Lys3</sup> decodes AAA and AAG in mRNA on the ribosome. The ms<sup>2</sup>- modification of t<sup>6</sup>A<sub>37</sub> results in ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> and is the product of Cdkal1 enzymatic activity. The modification ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> facilitates accurate and efficient decoding of the lysine codons. Domains are labeled. Anticodon loop modified nucleosides positions and structures are circled. The ms<sup>2</sup>- modification made by Cdkal1 is found with ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>. The anticodon 5'-adjacent invariant U and 3'-modified adenosine are noted.

**2. KEYWORDS:** Type 2 Diabetes; Cdkal1; tRNA modification; Decoding on the ribosome; Cdkal1 protein; insulin

**3. ACCOMPLISHMENTS:**

**What were the major goals of the project?**

**Aim 1: Conclude experiments for revision of manuscript**

Major Task 1: Characterize new murine knockout of *cdkal1* in a murine  $\beta$ -cell line.

Major Task 2: Isolate and characterize modifications of tRNA<sup>Lys3</sup>

Major Task 3: Submit manuscript revision

**Aim 2: Edit galley Proofs and resubmit**

**What was accomplished under these goals?**

**1) Major activities:**

- We characterized NIT-1 *cdkal1* knock down  $\beta$ -cells in culture as to their production of Cdkal and insulin. Characterization of a new murine knockout of *cdkal1* in a murine  $\beta$ -cell line was begun.
- tRNA was isolated and characterized for modifications of tRNA<sup>Lys3</sup> particularly t<sup>6</sup>A and ms<sup>2</sup>t<sup>6</sup>A.
- A manuscript was revised re-submitted, accepted, galley proofs corrected and published.

## 2) Specific objectives:

Cdkal1 knockout cell line validation with assessing *cdkal1* mRNA and Cdkal1 protein production.

Assessment of insulin mRNA and protein populations

Rescue *cdkal1*-deficient cells with transfection of human cDNA *cdkal1*.

MS analysis of insulin from Cdkal1 deficient and rescued cells

Design and purchase oligo probes to isolate tRNA<sup>Lys3</sup>

Isolate tRNA<sup>Lys3</sup> from *cdkal1*-deficient and *cdkal1* rescued cells and have modified nucleosides identified with HPLC/MS

Revise manuscript as suggested by reviewers

Submit revised manuscript

Have all 11 authors contribute editing


Compile edits and apply

Submit edited galleys


## 3) Significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative):

The NIT-1 cell line (ATCC<sup>®</sup> CRL-2055<sup>™</sup>) is inducible for insulin production with high glucose concentrations, theophylline and KCl (Figure 2A). The cells were stimulated to produce insulin with Theophylline (10 mM with 5.5 mM glucose) or KCl (40 mM) in SF media (Figure 2A). In order to determine the effect of a reduced Cdkal1 protein production, we knocked down *cdkal1* gene expression with two distinct methods. The *cdkal1* gene was knocked down by transfection of an esiRNA (endonuclease-prepared siRNA, 30, 50 or 70 nM using Lipofectamine, LF; Sigma) and by a Lentiviral shRNA (Sigma). Cells were also transfected with a control GFP esiRNA in antibiotic-free medium (6 h). Cells were glucose starved overnight in SF-DMEM, and induced for insulin (90 min) or left unstimulated (SF-DMEM with 600 KIU/mL aprotinin). Cells transfected with a control GFP esiRNA or Lipofectamine (LF RNAiMax reagent) alone responded to stimulation similar to cells that had not been transfected. Supernatants of *cdkal1* esiRNA (50 nM) knockdown cells assayed for insulin by ELISA had as low as 20% of the mature insulin production compared to a control esiRNA and LF-transfected cultures (Figure 2B). The cells were lysed in RIPA buffer with protease inhibitors and the lysates were processed for Western blots that showed decreased Cdkal1 protein as well as decreased insulin production (Supplemental Figure 1).

Cells were also infected with four different Lentiviral shRNA constructs against the *cdkal1* gene in antibiotic-free medium and selected with puromycin (3.5 µg). Clones, LC4, LC5, and LC7 that survived puromycin selection were




**Figure 2. A. Relative activation of insulin produced in stimulated NIT-1 cells.** NIT-1 cells plated in 24 wells for 48 h were serum starved overnight and stimulated for 90 mins with control (SF), Glucose (25 mM), Theophylline (10 mM in Glu 5.5), and KCl (40 mM) in SF medium with Aprotinin. **A. Insulin secretion in cell supernatants** was measured by ELISA using a mouse proinsulin and insulin antibody and concentration calculated using a human insulin protein standard curve. Insulin levels were normalized to control cells and expressed as fold-change over control (Relative Activation). Results are an average three biological experiments. \*\* indicates p value <0.01 using a Students t-test. **B. Insulin levels in supernatants from NIT-1 knockdown cells.** Secreted insulin levels from esiRNA-transfected (50 nM with LF 1 µl) NIT-1 cells were measured by ELISA following stimulation with KCl or Serum-free medium. Data is expressed as Relative Activation compared to unstimulated (SF) Lipofectamine RNAiMax (LF) - only transfected control cells. \*\*\* indicates p value <0.001 using a Students t-test. **C. Secreted insulin levels** from Lentiviral shRNA knockdown clones of NIT-1 cells (LC4, LC5 and LC7) were measured by ELISA following stimulation. Data is expressed as Relative Activation compared to non-stimulated control cells of each cell type. Experiments were controlled for the amounts of protein. **D. Insulin protein levels in esiRNA knockdown cell lysates.** Protein levels were normalized to GAPDH and expressed as Relative Densitometric Units (RDU).



expanded and DNA isolated and sequenced. Insulin induced cells were analyzed with the GSIR assay, ELISA and Western blot. Compared to normal NIT-1 cells, the secreted insulin levels were 50% or lower with stimulation by Theophylline and KCl (Figure 2C). When cell lysates were assayed for insulin, LC4 stimulated by KCl showed that the knockdown of *cdkal1* by the shRNA construct inhibited insulin production by >60% (Figure 2D). Analysis of stimulated NIT-1 cell lysates by Western blotting showed no significant changes in the levels of Cdkal1 protein in normal NIT-1 cells although knockdown cells had lower Cdkal1 protein levels (Figure 3). The amount of GAPDH control protein was not affected in the Cdkal1 deficient cells.

The function of Cdkal1 protein's modification of tRNA is accurate and efficient translation of AAG/AAA codons. Insulin mRNA requires the Cdkal1 modification of tRNA<sup>Lys3</sup> from t<sup>6</sup>A<sub>37</sub> to ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> for insertion of lysine at position 88. A significant decrease was observed in ms<sup>2</sup>t<sup>6</sup>A relative to t<sup>6</sup>A in RNA (<200 nts) isolated from cells that had been knocked down (Figure 4). We isolated RNA from esiRNA knockdown cells, stimulated and unstimulated for insulin production and control Lipofectamine only (LF) cells. The RNA was fractionated so that we could analyze small RNAs less than 200 nucleotides such as tRNAs without rRNA present (Ambion *mirVana* miRNA Isolation Kit). The RNA was hydrolyzed to nucleosides and the modified nucleoside analysis conducted by UHPLC-MS/MS (triple quadrupole MS (Waters MS)).<sup>16</sup> The ms<sup>2</sup>t<sup>6</sup>A modification decreased in tRNAs from esiRNA30 and esiRNA50 knockdown cells. As expected, the decrease was most dramatic in tRNA from esiRNA50 cells grown in SF medium, and less so when the cells were stimulated by KCl. The decrease of ms<sup>2</sup>t<sup>6</sup>A in tRNA is consistent with and probably the cause of a decrease in secreted insulin and increase in precursor insulin mRNA.

Large sequence RNA was isolated from normal and transfected knockdown NIT-1 cells (Qiagen RNeasy Plus kit) and rRNA was removed (Qiagen RNeasy MinElute Kit). Quantitative real-time PCR was conducted to determine the presence of *cdkal1*, precursor insulin, and mature insulin mRNAs.<sup>17</sup> Threshold Cq values were normalized to actin levels. Relative expression was calculated using the 2<sup>ΔΔCq</sup> method.<sup>18</sup> The expression of *cdkal1* mRNA levels







increased by ~60% in normal NIT-1 cells following stimulation with KCl (Figure 5A). However, in stimulated *cdkal1*-esiRNA treated knockdown cells, the mRNA levels were decreased by ~30% (Figure 5B). To determine the regulation of insulin transcription, we applied a unique strategy using two sets of primers that amplified total mouse insulin I and II mRNA (fully processed mature insulin mRNA) and a precursor mRNA species containing intron 2 (Figure 5C).<sup>17</sup> The levels of mature mRNA and precursor mRNA insulin levels were quantitated and expressed as the real time threshold cycle ( $C_T$ ) values, in untreated (SF) and KCl stimulated NIT-1 normal or knockdown cells. Although no differences were seen in mature insulin mRNA levels, significant changes in precursor insulin mRNA levels were detected with stimulation to produce insulin (Figure 5D). When the abundance of precursor insulin mRNA relative to mature insulin mRNA in control cells is normalized to 1.00, in stimulated *cdkal1* knockdown cells the ratio is 1.95 relative to mature insulin mRNA. In  $\beta$ -cells when the *cdkal1* gene is non-functional or missing and the tRNA<sup>Lys3</sup> modification ms<sup>2</sup>t<sup>6</sup>A has decreased, *cdkal1* mRNA has decreased 30% also. However, the insulin precursor mRNA is significantly increased. Thus, *cdkal1* knockdown cells stimulated to produce insulin are yet secreting less mature insulin. Lysates from these cells exhibited significantly decreased insulin and proinsulin.

We asked why should the modification ms<sup>2</sup>- play such an important role in tRNA<sup>Lys3</sup> in translating the lysine wobble codon AAG in insulin mRNA? When the anticodon U<sub>34</sub>U<sub>35</sub>U<sub>36</sub> with the adjacent ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> binds the wobble codon G3A2A1, the ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> is three nucleosides distant from the U<sub>34</sub>:G3 pair. There are three posttranscriptional modifications in the anticodon stem and loop (ASL) of tRNA<sup>Lys3</sup>, 5-methoxycarbonylmethyl-2-thiouridine at wobble position 34 (mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub>), 2-methylthio-N<sup>6</sup>-threonylcarbamoyladenosine at position 37 (ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>) adjacent to the anticodon and pseudouridine ( $\Psi$ <sub>39</sub>) at position 39 in the stem. The fully modified ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> and mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> are required to achieve wild-type binding activity of human tRNA<sup>Lys3</sup> to AAA and the wobble codon AAG. NMR structure determination and molecular dynamics simulations (MDS) of the ASL demonstrated that the ms<sup>2</sup>t<sup>6</sup>- modification of A<sub>37</sub> supports the anticodon nucleoside stack 5' to 3' and reduces solvent accessibility of U<sub>36</sub>.


To explore the role of the tRNA<sup>Lys3</sup> modifications at A<sub>37</sub> for recognition and decoding, we performed molecular simulations of the anticodon stem-loop of the tRNA (ASL) bound to the mRNA AAG at the A site of the eukaryotic ribosome. We compared three simulations with the ASL-mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> with A<sub>37</sub>, t<sup>6</sup>A<sub>37</sub>, and ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> each bound to the wobble codon AAG on the ribosome. First, we considered the effect of the modifications on the codon-anticodon interaction. We compared the hydrogen bonding between the codon and anticodon nucleosides (A1:U<sub>36</sub>, A2:U<sub>35</sub> and G3:mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub>), in the three systems (Figure 6). Interestingly, we observe that the hydrogen bonding is stronger for all three positions of the codon-anticodon base pairs by the addition of the t<sup>6</sup>-modification to A<sub>37</sub> and is further enhanced by the addition of the ms<sup>2</sup>- to t<sup>6</sup>A<sub>37</sub>. Remarkably, we find that this enhancement is most pronounced when the mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub>:G3 base-pair is considered, which is the farthest from the A<sub>37</sub>.



Next, we asked how does the modification at A<sub>37</sub> lead to significant strengthening of codon anticodon base-pairing? The dominant locations of the threonylcarbamoyl-group in both t<sup>6</sup>A<sub>37</sub> & ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> systems has the hydrophilic moieties of the modification (carboxyl and hydroxyl groups) either pointing away from the ASL cavity and remaining well hydrated or are involved in a cross-loop interaction with the backbone (2' hydroxyl group) of C<sub>32</sub> (Figure 7A). The rest of the modification fits inside the ASL cavity through hydrophobic and hydrogen bonding interactions, thereby offering stability to the neighboring codon-anticodon base-pairs. Furthermore, we observed transient interaction between the terminal methyl groups of ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> and mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> (Figure 7B), suggesting that the enhancement in stability due to the modification at A<sub>37</sub> extends to the codon-anticodon base pair farthest from A<sub>37</sub>. Most interestingly, we also found that the t<sup>6</sup>- group interaction with the ASL cavity is more stable with the addition of the ms<sup>2</sup>- group. The ms<sup>2</sup>-group boosts the stacking interaction between A<sub>37</sub> and the A1 codon of which the threonylcarbamoyl-group is held steady in the ASL cavity. Overall, our molecular simulations reveal a cascading mechanism for ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>, in which hydrogen bonding energy and the hydrophobic interactions of base-stacking by the methylthio-group stabilizes the threonylcarbamoyl-group in the ASL cavity. This in turn facilitates the hydrophobic interaction of the threonyl-carbamoyl-group with the methylcarboxymethyl- (mcm<sup>5</sup>-) group on U<sub>34</sub> three nucleosides away, stabilizing the codon-anticodon base-pairing at the wobble position for wobble codon AAG recognition.



**Figure 5. The hydrogen bond occupancy for the tRNA<sup>Lys3</sup> anticodon-codon base pairs.** The hydrogen bond (H-bond) occupancy for the tRNA<sup>Lys3</sup> anticodon-codon base pairs for the mcm<sup>5</sup>U<sub>34</sub>U<sub>35</sub>U<sub>36</sub> anticodon interacting with the A<sub>1</sub>A<sub>2</sub>G<sub>3</sub> wobble codon for the three cases of tRNA<sup>Lys3</sup>-A<sub>37</sub>, tRNA<sup>Lys3</sup>-t<sup>6</sup>A<sub>37</sub> and tRNA<sup>Lys3</sup>-ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>. The chart presents the H-bond occupancy for the percentage of the simulation time the base-pairs, A<sub>1</sub>:U<sub>36</sub>, A<sub>2</sub>:U<sub>35</sub>, G<sub>3</sub>:mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> interact and establish 0, 1, or 2 H-bonds.



**Figure 7. The dominant orientation of the hypermodified ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> shown in space filling model interacting with the anticodon stem loop cavity.** A. The terminal carboxyl group of the threonylcarbamoyl-group faces away from the ASL cavity, while the aliphatic carbons and the terminal methyl group fill up the cavity. Stacking between A<sub>1</sub>, A<sub>37</sub> and A<sub>38</sub> is enhanced by the addition of the thiomethyl-group to t<sup>6</sup>A<sub>37</sub>, ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>. B. The interaction between hypermodified ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> and mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> shown in space filling model. Hydrophobic contacts between the two modified nucleotides assists mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> in maintaining the anticodon:codon interaction at the wobble position.

Other achievements: Why does tRNA<sup>Lys3</sup> with the fully modified ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> decode the lysine wobble codon AAG-88 in β-cells, whereas tRNA<sup>Lys3</sup> lacking the fully modified ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> in cells deficient of Cdkal1 protein does not decode AAG? In humans, there are three lysine isoaccepting tRNAs that decode the lysine codons AAG and AAA. However, only tRNA<sup>Lys3</sup> with the anticodon composed of an extensively modified 5-methoxycarbonyl-2-thio-U<sub>34</sub>-UU<sub>36</sub> is able to decode AAA and also decode its wobble codon AAG. The other two lysine isoaccepting tRNAs have anticodons that are unmodified, C<sub>34</sub>-UU. The relative amounts of the three tRNA species in β-cells are unknown. Codon binding analyses have shown that the 5-methoxycarbonyl-2-thiouridine-34 (mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub>) and the ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> are important for decoding AAG. The ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> maintains in the NMR-restrained molecular dynamics derived solution structure, the anticodon in an open loop conformation required for ribosomal binding. With each of the two lysine codons bound into the A site in the 30S ribosomal subunit crystal structures, we observed that the tRNA<sup>Lys3</sup> modified nucleosides mcm<sup>5</sup>s<sup>2</sup>U<sub>34</sub> and ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub> participate in the stability of the anticodon/codon



interaction. Without a doubt, the modifications pre-structure the anticodon for effective and accurate recognition of cognate and wobble codons. The  $ms^2t^6$  modification of  $A_{37}$  is a prerequisite for maintaining this structure and reduces solvent accessibility of  $U_{36}$ . Modifications provide functional versatility to the tRNA through changes in chemical and structural environments. However, the way in which the  $ms^2$ -modification participates in the AAA and AAG codon recognition is not known, nor is the degree to which the modifications enhance the wobble versus cognate codon binding. We have used molecular dynamic simulations (MDS) to answer these questions, and we have recently found that the binding to the wobble codon AAG is most significantly enhanced by the  $ms^2t^6A_{37}$  by hydrophobic interactions and the removal of water molecules between codon and anticodon.

Stated goals were not fully met: We did not fully characterize the new murine knockout of *cdkal1* in a murine  $\beta$ -cell line. We wanted to rescue the line with transfection of the **human** *cdkal1*. Description of other pertinent data and graphs: Upon full examination of H-bonds between the codon and anticodon, we found that the average H-bond occupancy was no different for  $t^6A_{37}$  and  $ms^2t^6A_{37}$  (Figure 8). The modifications  $t^6A_{37}$  and  $ms^2t^6A_{37}$  provide added H-bond strength but there is no difference between the two. However, the  $ms^2$ - group affects the hydration of the ASL:codon helical cavity (Figure 9). Wobble decoding of  $G_3-U_{34}$  in the AAG codon by  $tRNA^{Lys3}$ , benefits from the modifications at both the 34<sup>th</sup> and the 37<sup>th</sup> position. The threonyl group of  $t^6A_{37}$  stabilizes the conformation of the anticodon stem loop via cross loop interactions with  $mcm^5s^2U_{34}$ . The methyl-thio group adds additional stability by holding the threonyl group in place, and further dehydrating the ASL.

4) A succinct description of the methodology used: NIT-1 is a  $\beta$ -cell line established from a transgenic mouse with the SV40 large T-antigen. It is grown in Hams F12K medium (F12K with L-Glutamine 90%; heat-inactivated, dialyzed fetal bovine serum 10%, FBS, Sigma; and 1 X penicillin-streptomycin, Invitrogen). Theophylline (10 mM with 5.5 mM glucose), glucose or KCl were used to stimulate insulin production. To knockdown the gene, we transfected an experimental esiRNA (endonuclease-prepared siRNA, Sigma) and a control GFP esiRNA with Lipofectamine 2000 and a Lentiviral shRNA (Sigma).

Stimulation of insulin production. NIT-1 has a glucose stimulated insulin response (GSIR) generated with a high glucose concentration (25 mM) when preceded by overnight incubation in low glucose, serum-free medium (SF-DMEM). Insulin production was assayed by ELISA (mouse proinsulin and insulin antibody, ABClonal)





Figure 9. Hydration of  $tRNA^{Lys3}$  anticodon bound to codon with  $t^6A_{37}$  vs.  $ms^2t^6A_{37}$ . The anticodon bound to the codon creates a cavity which has a degree of hydration depending on the hydrophobicity of the interaction. MDS show that the  $ms^2t^6A_{37}$  is more hydrophobic and repulses water thereby enhancing the modification's ability to cross duplex stack.

**Transfections.** Plated cells were transfected with a control GFP esiRNA or *cdk1* esiRNA (30, 50 or 70 nM using Lipofectamine, LF, RNAiMax reagent, 0.5 or 1  $\mu$ l, Invitrogen) in antibiotic-free medium (6 h). Cells were then incubated in fresh medium (48 h), serum and glucose starved overnight in SF-DMEM, and induced for insulin (90 min) or left unstimulated (SF-DMEM with 600 KIU/mL aprotinin).

**Modified Nucleoside Analysis.** Small RNAs (<200 nucleotides) were isolated (Ambion *mirVana* miRNA Isolation Kit) and the RNA was dialyzed extensively against phosphate buffer (10 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 6.8) and then against water (18 m $\Omega$ ). The RNA was hydrolyzed to nucleosides enzymatically rather than chemical digestion. The 2-step process cleaves first the phosphodiester bond with nuclease P1 resulting in nucleoside-5'-monophosphates followed by bacterial alkaline phosphatase (BAP) to cleave the 5'-phosphate from the nucleosides resulting in individual nucleosides and phosphoric acid. The modified nucleoside analysis was conducted by UHPLC-MS/MS (triple quadrupole MS (Waters MS)).

**RT-qPCR of insulin and *cdk1* mRNA.** We used RT-qPCR to assess the level of expression of mature insulin (mouse insulin I and II) or a pre-insulin or precursor containing intron 2 in normal and in esiRNA transfected NIT-1 cells, induced and not induced for insulin production. Large sequence RNA was isolated from normal and transfected knockdown NIT-1 cells (Qiagen RNEasy Plus kit) and rRNA was removed (Qiagen RNEasy MinElute Kit). A 2-step RT-PCR was conducted to determine the presence of *cdk1*, precursor insulin, and mature insulin mRNAs (BioRad 2step c-DNA Synthesis kit). The expression and amount of *cdk1* mRNA was determined by quantitative real-time PCR (RT-qPCR) analysis. Threshold C<sub>q</sub> values were normalized to actin levels. Relative expression was calculated using the 2 <sup>$\Delta\Delta C_q$</sup>  method.

**Molecular Dynamics Simulations.** The crystal structure of the mammalian ribosome was obtained from the Protein Data Bank (PDB ID: 5LZS). An intact stable fragment of structure was used for simulations, which included the mRNA, the anticodon stem loop (ASL) of the A-site tRNA, ribosomal RNA and ribosomal proteins within 25 Å of the codon and anticodon minihelix at the A-site. The ASL and the mRNA codon were modified to match the human tRNA<sup>Lys3</sup> ASL sequence and the lysine codon respectively using MOE. Six different constructs of the ASL:codon pair were modeled with codons AAA and AAG, each paired with the ASL containing the unmodified nucleoside A<sub>37</sub>, threonylcarbonyl-adenosine (t<sup>6</sup>A<sub>37</sub>) and hypermodified 2-methylthio N<sup>6</sup>-threonylcarbonyl-adenosine (ms<sup>2</sup>t<sup>6</sup>A<sub>37</sub>). In order to simulate the modified tRNA, AMBER type force-field parameters were developed for the atoms of the modified nucleosides – pseudouridine<sup>Ψ</sup>, mcm<sup>5</sup>s<sup>2</sup>U, t<sup>6</sup>A and ms<sup>2</sup>t<sup>6</sup>A. The geometry of the modified nucleosides was optimized using Hatree-Fock level theory and 6-31G\* basis-sets in Webmo. For obtaining the partial charges on the atoms, the online RESP charge-fitting server REDS was used. AMBER-99 force field parameters and AMBER-99 parameters with the Chen-Garcia correction were used for bonded and Lennard-Jones (LJ) interactions, respectively. Molecular dynamics (MD) simulations were performed using Gromacs-2016.4 and Gromacs-2019.6 packages. The MD simulations incorporated a leap-frog algorithm with a 2-fs timestep to integrate the equations of motion. The system was maintained at 300K, using the velocity rescaling thermostat. The pressure was maintained at 1 atm using the Berendsen barostat for equilibration. Long-range electrostatic interactions were calculated using particle mesh Ewald (PME) algorithm with a real space cut-off of 1.0 nm. LJ interactions were truncated at 1.0 nm. The TIP3P model was used to represent the water molecules, and the LINCS algorithm was used to constrain the motion of hydrogen atoms bonded to heavy atoms. The system was subjected to energy minimization to prevent any overlap of atoms, followed by 0.5 ns of equilibration and a 25-ns production run. During simulations, the ribosomal RNA, proteins and the mRNA (except the codon) were held in place using position restraints on the heavy atoms of the RNA and protein backbone with a force constant of 1000 Newton/nm in each spatial dimension for the simulation. Coordinates of the ribosomal fragment (rRNA, tRNA, and mRNA) were stored every 1 ps for further analysis. The simulations were visualized using Visual Molecular Dynamics software and analyzed using tools from Gromacs.

### **What opportunities for training and professional development has the project provided?**

- Training activities. The project provided training for postdocs and undergraduate students. They were able to work with Dr. Agris one-on-one to advance skills and experience and assist others in learning. Postdocs were able to increase knowledge and skill sets, attend conferences, and seminars, and present seminars.

○ **How were the results disseminated to communities of interest?**

Results and conclusions were disseminated through the publication and through seminars and poster presentations

○ **What do you plan to do during the next reporting period to accomplish the goals?**

Nothing to Report.

**IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

○ **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to Report; too early.

○ **What was the impact on other disciplines?**

Nothing to Report; too early.

○ **What was the impact on technology transfer?**

Nothing to Report; too early.

○ **What was the impact on society beyond science and technology?**

Nothing to Report; too early.

**CHANGES/PROBLEMS: Changes in approach and reasons for change**

Nothing to Report.

**Actual or anticipated problems or delays and actions or plans to resolve them**

We anticipated that the knockdown would be more effective. We had to move on to a knockout of the endogenous *cdkal1*. The knockouts apparently are almost 100% effective.

**Changes that had a significant impact on expenditures**

Nothing to Report

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to Report

**Significant changes in use or care of human subjects.** Not applicable

○ **Significant changes in use or care of vertebrate animals.** Not applicable

○ **Significant changes in use of biohazards and/or select agents.** Not applicable

**PRODUCTS:** *Cdkal1* knockout cell line.

**Publications, conference papers, and presentations**

▪ **Journal publications.**

Narendran Amithi, Vangaveti Sweta, Ranganathan Srivathsan V., Eruysal Emily, Craft Miranda, Alrifai Omar, Chua Fu Yee, Sarachan Kathryn, Litwa Breann, Ramachandran Sheetal, Agris Paul F. Silencing of the tRNA Modification Enzyme Cdkal1 Effects Functional Insulin Synthesis in NIT-1 Cells: tRNALys3 Lacking ms2-(ms2t6A37) is Unable to Establish Sufficient Anticodon:Codon Interactions to Decode the Wobble Codon AAG *Frontiers in Molecular Biosciences*, 7: 584228. Published online 2021 Feb 9.

Federal support (yes).

**Books or other non-periodical, one-time publications.** Nothing to Report

**Other publications, conference papers, and presentations.** Nothing to Report

**Website(s) or other Internet site(s)** Nothing to Report

**Technologies or techniques** Nothing to Report

**Inventions, patent applications, and/or licenses** Nothing to Report

**Other Products** Nothing to Report **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

○ **What individuals have worked on the project?**

|                                        |                  |
|----------------------------------------|------------------|
| Name:                                  | Amithi Narendran |
| Project Role:                          | Lab manager      |
| Researcher Identifier (e.g. ORCID ID): |                  |

|                                        |                                                                                                                   |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Nearest person month worked:           | 12                                                                                                                |
| Contribution to Project:               | Ms. Narendran has performed work in the area of cell culture, knock downs, Wester blots.                          |
| Funding Support:                       |                                                                                                                   |
| Name:                                  | Sweta Vangaveti                                                                                                   |
| Project Role:                          | Senior postdoc                                                                                                    |
| Researcher Identifier (e.g. ORCID ID): |                                                                                                                   |
| Nearest person month worked:           | 9                                                                                                                 |
| Contribution to Project:               | Dr. Vangaveti conducted MDS and interpretation                                                                    |
| Funding Support:                       |                                                                                                                   |
| Name:                                  | Srivathsan V. Ranganathan                                                                                         |
| Project Role:                          | Senior postdoc                                                                                                    |
| Researcher Identifier (e.g. ORCID ID): |                                                                                                                   |
| Nearest person month worked:           | 9                                                                                                                 |
| Contribution to Project:               | Dr. Ranganathan conducted MDS and interpretation                                                                  |
| Funding Support:                       |                                                                                                                   |
| Name:                                  | Emily Eruysal, Miranda Craft, Omar Alrifai, Fu Yee Chua, Emily Eruysal, Miranda Craft, Omar Alrifai, Fu Yee Chua, |
| Project Role:                          | Undergraduate researchers                                                                                         |
| Researcher Identifier (e.g. ORCID ID): |                                                                                                                   |
| Nearest person month worked:           | 6                                                                                                                 |
| Contribution to Project:               | Assay development and application                                                                                 |
| Funding Support:                       |                                                                                                                   |

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?** No

**What other organizations were involved as partners?**

Nothing to Report.

#### **SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:** None.